[go: up one dir, main page]

TW200800966A - Beta-secretase modulators and methods of use - Google Patents

Beta-secretase modulators and methods of use

Info

Publication number
TW200800966A
TW200800966A TW095143035A TW95143035A TW200800966A TW 200800966 A TW200800966 A TW 200800966A TW 095143035 A TW095143035 A TW 095143035A TW 95143035 A TW95143035 A TW 95143035A TW 200800966 A TW200800966 A TW 200800966A
Authority
TW
Taiwan
Prior art keywords
compounds
beta
methods
formula
treatment
Prior art date
Application number
TW095143035A
Other languages
Chinese (zh)
Inventor
Wenge Zhong
Stephen Hitchcock
Brian K Albrecht
Michael Bartberger
James Brown
Ryan Brown
Stuart Charles Chaffee
Yuan Cheng
Michael Croghan
Russell Graceffa
Scott Harried
Dean Hickman
Dan Horne
Randall Hungate
Ted Judd
Matthew Kaller
Charles Kreiman
Daniel La
Patricia Lopez
Holger Monenschein
Thomas Nguyen
Thomas Nixey
Vinod F Patel
Lewis Pennington
Matthew Weiss
Qiufen Xue
Bryant Yang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39708735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200800966(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TW200800966A publication Critical patent/TW200800966A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I Wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
TW095143035A 2005-11-21 2006-11-21 Beta-secretase modulators and methods of use TW200800966A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73910805P 2005-11-21 2005-11-21
US85482406P 2006-10-27 2006-10-27

Publications (1)

Publication Number Publication Date
TW200800966A true TW200800966A (en) 2008-01-01

Family

ID=39708735

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095143035A TW200800966A (en) 2005-11-21 2006-11-21 Beta-secretase modulators and methods of use

Country Status (8)

Country Link
EP (1) EP1971598A1 (en)
JP (1) JP5274258B2 (en)
AR (1) AR057985A1 (en)
AU (1) AU2006316620B2 (en)
CA (1) CA2629402C (en)
PE (1) PE20070645A1 (en)
TW (1) TW200800966A (en)
WO (1) WO2007061670A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200901991A (en) * 2007-05-25 2009-01-16 Amgen Inc Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
EP2167471B1 (en) * 2007-05-25 2013-10-16 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
CN103687839B (en) 2011-07-21 2016-06-08 通用电气健康护理有限公司 Precursor compound and preparation method thereof
US9493485B2 (en) 2012-03-20 2016-11-15 Imago Pharmaceuticals, Inc. Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof
US9932333B2 (en) 2014-07-16 2018-04-03 Japan Science And Technology Agency Benzothiazole compound and medicine containing same
TW202100526A (en) 2019-03-06 2021-01-01 日商第一三共股份有限公司 Pyrrolopyrazole derivatives

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
MXPA02012560A (en) 2000-06-30 2003-05-14 Elan Pharm Inc Compounds to treat alzheimer s disease.
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
US6982264B2 (en) 2001-06-27 2006-01-03 Elan Pharmaceuticals, Inc. Substituted alcohols useful in treatment of Alzheimer's disease
KR100713137B1 (en) 2001-06-28 2007-05-02 동화약품공업주식회사 Novel 2,4-difluorobenzamide derivatives
MXPA04000338A (en) 2001-07-10 2004-07-23 Upjohn Co Diaminediols for the treatment of alzheimer's disease.
CA2453447A1 (en) 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease
EP1409450B1 (en) 2001-07-11 2009-12-09 Elan Pharmaceuticals, Inc. N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
US7244755B2 (en) 2001-10-04 2007-07-17 Pharmacia & Upjohn Company Hydroxypropylamines
AU2002335794A1 (en) 2001-10-05 2003-04-22 Elan Pharmaceuticals, Inc Allylamides useful in the treatment of alzheimer's disease
JP2005535559A (en) 2001-10-29 2005-11-24 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Hydroxy-substituted amides for the treatment of Alzheimer's disease
EP1453789A2 (en) 2001-11-08 2004-09-08 Elan Pharmaceuticals, Inc. N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives
TW200304374A (en) 2001-11-30 2003-10-01 Smithkline Beecham Plc Novel compounds
BR0214736A (en) 2001-12-06 2004-11-23 Elan Pharm Inc Compound and its pharmaceutically acceptable salts, pharmaceutical composition and method of treating humans or animals suffering from diseases or conditions
JP2005534614A (en) 2002-01-04 2005-11-17 イーラン ファーマスーティカルズ、インコーポレイテッド Substituted aminocarboxamides for the treatment of Alzheimer's disease
EP1471910A2 (en) 2002-01-17 2004-11-03 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
AU2003276047A1 (en) 2002-06-17 2003-12-31 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US7115747B2 (en) 2002-06-20 2006-10-03 Pharmacia & Upjohn Company Process for preparing oxazole intermediates
UY27967A1 (en) 2002-09-10 2004-05-31 Pfizer 2-HINDROXI-1,3-DIAMINOALCANE OIL
US7362070B2 (en) 2002-11-04 2008-04-22 Hamilton Sundstrand Corporation Electric motor control system including position determination and error correction
CA2505098A1 (en) 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004050609A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
CA2512111A1 (en) 2003-01-07 2004-07-29 Merck And Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
US20060241133A1 (en) 2003-03-14 2006-10-26 Shearman Mark S Electrically variable pneumatic structural element
GB0305918D0 (en) 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
CA2522805A1 (en) * 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. Phenacyl 2-hydroxy-3-diaminoalkanes
MXPA05011150A (en) 2003-04-21 2005-12-14 Elan Pharm Inc (HETERO) ARYLAMIDE 2-HYDROXY-3-DIAMINOALKANES FOR USE IN THE TREATMENT OF ALZHEIMERaCOES DISEASE.
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
WO2005005374A1 (en) 2003-06-16 2005-01-20 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
CN100430377C (en) 2003-06-30 2008-11-05 麦克公司 N-alkylphenylcarboxamide beta secretase inhibitors for the treatment of alzheimer's disease
EP1643986A4 (en) 2003-07-01 2009-04-08 Merck & Co Inc PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
GB0317491D0 (en) * 2003-07-25 2003-08-27 Novartis Ag Organic compounds
JP2007522129A (en) * 2004-01-21 2007-08-09 エラン ファーマシューティカルズ，インコーポレイテッド Methods for treating amyloidosis using aspartic protease inhibitors
JP2007528403A (en) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド Methods for treating amyloidosis using bicyclic aspartic protease inhibitors
JP2007530583A (en) * 2004-03-25 2007-11-01 イーラン ファーマスーティカルズ、インコーポレイテッド 2-Amino- and 2-thio substituted 1,3-diaminopropane

Also Published As

Publication number Publication date
PE20070645A1 (en) 2007-08-24
JP2009516684A (en) 2009-04-23
AR057985A1 (en) 2008-01-09
CA2629402C (en) 2011-07-26
WO2007061670A1 (en) 2007-05-31
JP5274258B2 (en) 2013-08-28
EP1971598A1 (en) 2008-09-24
CA2629402A1 (en) 2007-05-31
AU2006316620A1 (en) 2007-05-31
AU2006316620B2 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
IS7925A (en) Hydroxyethylamine derivatives for the treatment of Alzheimer's disease
ZA201002115B (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
MX2010009752A (en) Oxadiazoanthracene compounds for the treatment of diabetes.
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
ATE517861T1 (en) BENZYL ETHER AND BENZYLAMIN COMPOUNDS AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
IL205002A0 (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
CY1111070T1 (en) 2-AMINE-QUINAZOLINE DERIVATIVE USEFUL FOR B-SECRETARISE INHIBITORS (BACE)
IL205003A0 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
HU0302788D0 (en) New compounds
ATE538651T1 (en) SPIROPIPERIDINE INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
DE602005023782D1 (en) PYRROLIDINE DERIVATIVES FOR TREATING A DISEASE DEPENDENT ON RENINACTIVITY
TW200700061A (en) Organic compounds
GB0328900D0 (en) Novel compounds
ATE512147T1 (en) MACROCYCLIC AMINIOPYRIDYL BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
TW200800966A (en) Beta-secretase modulators and methods of use
WO2007019078A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
TNSN08287A1 (en) 3,5-substituted piperidine compounds as renin inhibitors
WO2007019111A3 (en) Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
TNSN06372A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TN2010000373A1 (en) The present invention provides oxadiazoanthracene